Close Menu

Opko

The firm's subsidiary BioReference Laboratories performed 3.5 million COVID-19 PCR tests and 300,000 serology tests during the quarter.

News items for in vitro diagnostics industry for the week of August 31, 2020.

Of the 28 companies in the index, 12 firms saw their stock prices increase, while 16 firms' share prices decreased. 

While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.

GeneDx will provide whole-exome and whole-genome sequencing, among other services, to neonatal intensive care units staffed with Pediatrix-affiliated doctors.

Of the 28 companies in the index, 22 firms saw their stock prices increase, while six firms' share prices decreased.

Opko's BioReference Laboratories business processed about 2.2 million COVID-19 molecular tests during the quarter, it said.

The company's revenues for its 4Kscore prostate cancer test were impacted partially by the COVID-19 pandemic, Opko said.

A number of labs have said that not only are they able to fulfill all current PCR test requests, but that they are operating at below capacity for these tests.

Pages